Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 13;81(4):719-733.
doi: 10.31053/1853.0605.v81.n4.44652.

[Effects of statins on bone mineral density of postmenopausal women from Córdoba, Argentina]

[Article in Spanish]
Pablo José Astesana  1 , Paula Beatriz Alba  1 , Carla Andrea Gobbi  1 , Eduardo Horacio Albiero  1 , Marcelo Augusto Yorio  1
Affiliations

[Effects of statins on bone mineral density of postmenopausal women from Córdoba, Argentina]

[Article in Spanish]
Pablo José Astesana et al. Rev Fac Cien Med Univ Nac Cordoba. .

Abstract
in English, Spanish

New evidence has emerged on pleiotropic properties of Statins (St), that would be potentially beneficial in the treatment of osteoporosis (OP)

Our objective was to study the effect of St on bone mineral density (BMD) in postmenopausal women.

Methods: This is a cross-sectional, analytical study, that analyze postmenopausal women with hypercholesterolemia who received treatment with St for at least 6 months, and as a control group (CG), postmenopausal women who did not receive St assisted in two rheumatology services in the city of Córdoba from August 2014 to September 2018.

Results: 202 postmenopausal women received St and 203 constituted the CG. The average age, weight and BMI were 62.54 years, 69.60 kg and 27.13 in the St group vs 58.58 years, 65.70 kg and 26.83 in the control group (p= 0.0001, p= 0.01, p=ns respectively). Lumbar, femoral neck and total hip BMD were statistically higher in patients who received St than in controls (-0.87 vs -1.74 p=0.00, - 1.15 vs 1.56 p= 0.00 and - 0.33 vs - 0.75 p= 0.01). Regarding the time of St treatment, a significant difference was found only in relation to BMD and lumbar spine between the groups of 6 to 12 months and those that received between 12 and 36 months. No relationship was found between BMD and the different types of St received.

Conclusion: Treatment with St could improve BMD in hypercholesterolemic postmenopausal women who takes these drugs.

Nuevas evidencias han surgido sobre propiedades pleiotrópicas de las Estatinas (ES) potencialmente beneficiosas en el tratamiento de la osteoporosis (OP). Nuestro objetivo fue estudiar el efecto de las ES sobre la densidad mineral ósea (DMO) en mujeres posmenopáusicas.

Métodos: Estudio de corte transversal, analítico, se estudiaron mujeres posmenopáusicas con hipercolesterolemia que recibieron tratamiento con ES de al menos 6 meses de duración, y como grupo control (GC) mujeres posmenopáusicas que no recibieron ES asistidas en dos servicios de reumatología de la ciudad de Córdoba desde agosto de 2014 hasta septiembre de 2018.

Resultados: 202 mujeres posmenopáusicas recibieron estatinas (ES) y 203 constituyeron el GC. La edad promedio, peso e IMC fue de 62,54 años, 69,60 kg y 27,13 en el grupo ES vs 58,58 años, 65,70 kg y 26,83 en el grupo control (p= 0,0001, p= 0,01, p=ns respectivamente). La DMO lumbar, de cuello femoral y de cadera total fue estadísticamente más alta en pacientes que recibieron ES que en controles (-0,87 vs -1,74 p=0,00, - 1.15 vs 1,56 p= 0,00 y - 0,33 vs - 0,75 p= 0,01). En cuanto al tiempo de tratamiento ES, se encontró diferencia significativa solamente en relación a DMO y columna lumbar entre los grupos de 6 a 12 meses y los que recibieron entre 12 y 36 meses. No se encontró relación entre la DMO y los diferentes tipos de ES recibidas.

Conclusión: El tratamiento con ES podría ser beneficioso en mejorar la DMO en mujeres posmenopáusicas hipercolesterolémicas medicados con dichos fármacos

Keywords: bone mineral density; statins; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

Conflicto de interés:

Ninguno.

Figures

Figura 1
Figura 1. Tiempo de consumo de estatinas y DMO
See this image and copyright information in PMC

References

    1. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020 May 15;133(1):105–117. doi: 10.1093/bmb/ldaa005. - DOI - PMC - PubMed
    1. Aziziyeh R, Amin M, Habib M, Garcia Perlaza J, Szafranski K, McTavish RK, Disher T, Lüdke A, Cameron C. The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina . J Med Econ. 2019 Jul;22(7):638–644. doi: 10.1080/13696998.2019.1590843. - DOI - PubMed
    1. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049–2102. doi: 10.1007/s00198-021-05900-y. Epub 2022 Apr 28. Erratum in: Osteoporos Int. 2022 Jul 28; - DOI - PMC - PubMed
    1. Zhou J, Wang T, Zhao X, Miller DR, Zhai S. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses . Rheumatol Ther. 2016 Jun;3(1):117–128. doi: 10.1007/s40744-016-0030-6. - DOI - PMC - PubMed
    1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy . J Clin Endocrinol Metab. 2005 Mar;90(3):1294–301. doi: 10.1210/jc.2004-0952. - DOI - PubMed

Publication types

Substances

LinkOut - more resources